Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23754
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Johnson, E. O. | en |
dc.contributor.author | Konstandi, M. | en |
dc.contributor.author | Babis, G. C. | en |
dc.contributor.author | Piagkou, M. | en |
dc.contributor.author | Soucacos, P. N. | en |
dc.date.accessioned | 2015-11-24T19:35:49Z | - |
dc.date.available | 2015-11-24T19:35:49Z | - |
dc.identifier.issn | 1875-6212 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23754 | - |
dc.rights | Default Licence | - |
dc.subject | Animals | en |
dc.subject | Anticoagulants/*pharmacology/*therapeutic use | en |
dc.subject | Blood Coagulation/*drug effects | en |
dc.subject | Clinical Trials as Topic | en |
dc.subject | Fibrinolytic Agents/pharmacology/therapeutic use | en |
dc.subject | Humans | en |
dc.subject | Lower Extremity/*surgery | en |
dc.subject | Orthopedic Procedures/*adverse effects/methods | en |
dc.subject | Venous Thromboembolism/*blood/*prevention & control | en |
dc.title | The plasma coagulation cascade: potential targets for novel anticoagulants in major lower limb surgery | en |
heal.type | journalArticle | - |
heal.type.en | Journal article | en |
heal.type.el | Άρθρο Περιοδικού | el |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21044025 | - |
heal.language | en | - |
heal.access | campus | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.publicationDate | 2011 | - |
heal.abstract | Strategies for prevention of venous thromboembolism in orthopaedic patients undergoing major lower limb surgery include pharmacological prophylaxis. Over the last three decades, the search for new safe and effective approaches for the prevention of venous thromboembolism in these patients has continued. Increased understanding of the haemostatic process has led to a clearer appreciation of the mechanisms of action of antithrombotic drugs already in use as well as the identification of new targets for novel drug development. As a result, the development of new anticoagulants has advanced rapidly over recent years. The molecular targets of several novel anticoagulants, and their effectiveness in early Phase II and Phase III trials are reviewed. | en |
heal.journalName | Curr Vasc Pharmacol | en |
heal.journalType | peer-reviewed | - |
heal.fullTextAvailability | TRUE | - |
Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License